Table 2.

Senolytic and immunomodulatory agents currently in clinical or preclinical use.

Name	Drug Class	Clinical Stage	References
Dasatinib	Tyrosine kinase inhibitor	Preclinical	[229]
Quercetin	Flavonoid	Preclinical	[229]
RAD001	mTOR inhibitor	Phase II	[230]
Nizatidine	Histamine receptor agonist	Preclinical	[231]
Cyclophosphamide	Immunosuppressant	Phase I/II	[232]
sVEGFR1/R2	VEGF inhibitor	Preclinical	[233]

mTOR: mammalian target of rapamycin

VEGF: vascular endothelial growth factor